OBJECTIVE: Although neurodevelopmental outcomes related to the management of patent ductus arteriosus with intravenous indomethacin and ibuprofen are known, little data on the long-term effects of oral ibuprofen can be found in the literature. METHOD: A follow-up study of 99 infants with birth weight ≤ 1,500 g and gestational age ≤ 32 weeks who received eitheroral or intravenous ibuprofenfor patent ductus arteriosus was conducted to assess at 18 to 24 months (corrected age), abnormal neurological, neurosensory, and cognitive impairment were defined as follows:neurological outcomes included moderate/severe cerebral palsy, neurosensory outcomes included bilateral hearing loss and blindness in either eye, and cognitive impairment included mental developmental index score < 70. RESULTS: The 18- to 24-month (corrected age) long-term outcomes of 30 subjects who receivedoral ibuprofen were compared with 27 subjects who receivedintravenous ibuprofen by certified and experienced examiners who were blind to the definitions of the groups. The results revealed that the long-term outcomes of the treatment regimens did not significantly differ. CONCLUSIONS:Preterm infants who were treated withoral ibuprofen for patent ductus arteriosus had similar neurological, neurosensory, and cognitive outcomes to patients who received intravenous ibuprofen at 2 years of age. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
RCT Entities:
OBJECTIVE: Although neurodevelopmental outcomes related to the management of patent ductus arteriosus with intravenous indomethacin and ibuprofen are known, little data on the long-term effects of oral ibuprofen can be found in the literature. METHOD: A follow-up study of 99 infants with birth weight ≤ 1,500 g and gestational age ≤ 32 weeks who received either oral or intravenous ibuprofen for patent ductus arteriosus was conducted to assess at 18 to 24 months (corrected age), abnormal neurological, neurosensory, and cognitive impairment were defined as follows:neurological outcomes included moderate/severe cerebral palsy, neurosensory outcomes included bilateral hearing loss and blindness in either eye, and cognitive impairment included mental developmental index score < 70. RESULTS: The 18- to 24-month (corrected age) long-term outcomes of 30 subjects who received oral ibuprofen were compared with 27 subjects who received intravenous ibuprofen by certified and experienced examiners who were blind to the definitions of the groups. The results revealed that the long-term outcomes of the treatment regimens did not significantly differ. CONCLUSIONS: Preterm infants who were treated with oral ibuprofen for patent ductus arteriosus had similar neurological, neurosensory, and cognitive outcomes to patients who received intravenous ibuprofen at 2 years of age. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Authors: Ömer Erdeve; Emel Okulu; Yogen Singh; Richard Sindelar; Mehmet Yekta Oncel; Gianluca Terrin; Giovanni Boscarino; Ali Bülbül; Hannes Sallmon; Begüm Atasay; Fahri Ovalı; Ronald I Clyman Journal: Turk Arch Pediatr Date: 2022-03
Authors: Tim Hundscheid; Wes Onland; Bart van Overmeire; Peter Dijk; Anton H L C van Kaam; Koen P Dijkman; Elisabeth M W Kooi; Eduardo Villamor; André A Kroon; Remco Visser; Daniel C Vijlbrief; Susanne M de Tollenaer; Filip Cools; David van Laere; Anne-Britt Johansson; Catheline Hocq; Alexandra Zecic; Eddy Adang; Rogier Donders; Willem de Vries; Arno F J van Heijst; Willem P de Boode Journal: BMC Pediatr Date: 2018-08-04 Impact factor: 2.125